<DOC>
	<DOC>NCT01197066</DOC>
	<brief_summary>This is a phase â…¢ multicenter, open-label, follow-up study, to assess the safety and efficacy of certolizumab pegol (CZP) as additional medication to methotrexate (MTX), in patients with active rheumatoid arthritis (RA) who participated in Study (Protocol) # 101-KOA-0801i.</brief_summary>
	<brief_title>Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Failed to achieve an ACR20 response at Week 12 in the Study 101KOA0801i or completed the entire Study 101KOA0801i through Week 24 Have a clear chest Xray at the Entry visit Negative urine pregnancy test at the Entry Continue treatment on methotrexate Any other inflammatory arthritis (e.g., psoriatic arthritis, ankylosing spondylitis or reactive arthritis) Secondary, noninflammatory type of arthritis (eg, osteoarthritis, fibromyalgia) At study entry taking any of the prohibited medications as detailed in the Study (Protocol) # 101KOA0801i NYHA (New York Heart Association) Class III or IV congestive heart failure Current or history of tuberculosis History of chronic infection, recent serious or lifethreatening infection or any current sign or symptom that may indicate an infection (e.g., fever, cough) History of a lymphoproliferative disorder including lymphoma or signs and symptoms suggesting lymphoproliferative disease High risk of infection Female breast feeding, pregnant or plan to become pregnant during the trial or for 12 weeks following the last dose of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>